Severe Shiga toxin–producing E. coli (STEC) infection: What to do

Do NOT give antibiotics or antidiarrheals; provide early, targeted supportive care with close monitoring for HUS and renal failure. 1

Immediate actions (prioritize morbidity, mortality, QoL)

Diagnose fast:
- Order stool Shiga toxin PCR/EIA plus O157 culture simultaneously; notify public health if positive 2.
Volume and renal protection:
- Start isotonic IV fluids early if dehydrated or hemodynamically unstable; avoid fluid overload, especially if oligo/anuric or evolving HUS; maintain net-even balance once AKI/oligoanuria develops 2, 3.
Withhold harmful meds:
- Avoid antibiotics (fluoroquinolones, β‑lactams, TMP‑SMX, metronidazole, and macrolides) due to evidence of harm and no proven benefit, particularly for O157 or Stx2‑producing strains 1.
- Avoid antidiarrheals (risk of complications) 1.
Monitor closely (q12–24h initially):
- CBC with smear, platelets; CMP (BUN/Cr, electrolytes), LDH, haptoglobin, urinalysis; strict I/O, weight, vitals; watch for HUS triad (thrombocytopenia, MAHA, AKI) 2, 1.

Early nephrology involvement; initiate dialysis for standard indications (refractory hyperkalemia, acidosis, volume overload, uremic complications) 4.
Transfuse PRBCs for symptomatic anemia; avoid prophylactic platelets unless bleeding or procedure planned 4.
Manage hypertension, electrolytes; avoid nephrotoxins and contrast 4.
No role for plasma exchange in typical STEC‑HUS; reserve for suspected TTP/atypical HUS differentials 4.

Guideline anchor: IDSA 2017 decisively recommends avoiding antibiotics in STEC O157 and Stx2‑producing non‑O157 because of harm signals and lack of benefit; also advises avoiding macrolides given insufficient benefit and possible harm; antidiarrheals discouraged 1. This is the most recent, high‑quality, prescriptive guidance provided.
Research context:
- Meta‑analysis of low‑bias studies: antibiotics associated with higher HUS risk (OR ~2.24) 5; expert review concurs—no convincing benefit, potential harm 6.
- A Japanese case‑control suggested possible fosfomycin benefit in children, but observational design and mixed results across ages and agents limit applicability; guidelines still advise avoidance when STEC suspected/confirmed 7, 1.
- Adult outbreak data suggest pediatric “aggressive” fluid targets may not translate; excessive volumes linked to dialysis need—use judicious isotonic fluids, titrated to perfusion and urine output 3.

Order stool Shiga toxin PCR/EIA + O157 culture immediately; isolate patient; report positives 2.
Start IV isotonic fluids if hypovolemic; avoid overload; reassess frequently; stop escalation if oligo/anuria and target net-even balance 2, 3.
Absolutely avoid antibiotics and antidiarrheals pending results; continue to avoid if STEC confirmed or not excluded and severe/bloody diarrhea present 1.
Daily labs and clinical monitoring for HUS; lower threshold for admission if bloody diarrhea, rising Cr, falling platelets/Hb, or severe pain 2, 1.
If HUS: nephrology consult, dialysis as indicated; PRBCs as needed; manage BP/electrolytes; no plasma exchange unless alternate TMA suspected 4.
Discharge only when hydrated, pain controlled, stable labs, and reliable follow‑up.

Starting empiric antibiotics in bloody diarrhea before ruling out STEC (increases HUS risk) 1, 5.
Giving loperamide or other antimotility agents (associated with worse outcomes) 1.
Over-resuscitation with fluids in adults with evolving AKI/HUS (risk of pulmonary edema, dialysis) 3.
Delayed stool testing and public health notification (missed outbreak control, delayed supportive care) 2.